A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
Metformin is the first line drug for patients diagnosed with type-2 diabetes; however, the impact of different treatment escalation strategies after metformin failure has thus far not been investigated in a real world situation. The registry described herein goes some way to clarifying treatment out...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
03 February 2015
|
| In: |
Cardiovascular diabetology
Year: 2015, Volume: 14, Pages: 1-8 |
| ISSN: | 1475-2840 |
| DOI: | 10.1186/s12933-015-0172-9 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12933-015-0172-9
|
| Author Notes: | Anselm K. Gitt, Peter Bramlage, Steffen Schneider and Diethelm Tschöpe |
| Summary: | Metformin is the first line drug for patients diagnosed with type-2 diabetes; however, the impact of different treatment escalation strategies after metformin failure has thus far not been investigated in a real world situation. The registry described herein goes some way to clarifying treatment outcomes in such patients. |
|---|---|
| Item Description: | Gesehen am 11.08.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1475-2840 |
| DOI: | 10.1186/s12933-015-0172-9 |